Physician profile
Amanda Victoria Wright
NPI 1679065577
$5,721.86
in general payments reported to CMS, 2019-2025
44 companies · $921 in 2025
The $921 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.80 · 2022: $1,905 · 2023: $1,577 · 2024: $1,295 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,780 · Entertainment: $13.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,780.22 |
| Entertainment | $13.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $939.72 | 2022-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $559.08 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $363.38 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $312.17 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $310.97 | 2022-2024 | Farxiga, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $282.14 | 2022-2023 | Trelegy Ellipta |
| Exact Sciences Corporation | $279.09 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $255.49 | 2022-2025 | |
| Amarin Pharma, INC. | $227.21 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.25 | 2022-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $164.75 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $163.87 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $148.33 | 2023 | |
| Corcept Therapeutics | $146.54 | 2023-2025 | Korlym |
| Dexcom, INC. | $144.85 | 2022-2025 | Dexcom G6 Transmitter |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $124.04 | 2022-2025 | Repatha, Krystexxa, Repatha |
| Boston Scientific Corporation | $117.63 | 2022-2025 | General - Pain Management |
| Almatica Pharma LLC | $105.65 | 2022-2023 | Loreev Xr, Gralise |
| Biohaven Pharmaceutical Holding Company LTD. | $90.35 | 2022 | |
| Tandem Diabetes Care, INC. | $82.60 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.88 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.00 | 2022-2023 | Jardiance |
| Xeris Pharmaceuticals, INC. | $61.61 | 2024 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $54.72 | 2022-2023 | Eliquis |
| Shield Therapeutics INC | $47.93 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $45.69 | 2021-2023 | Xarelto |
| Horizon Therapeutics Plc | $38.79 | 2023 | Krystexxa |
| Idorsia Pharmaceuticals US INC | $35.17 | 2022-2023 | Quviviq |
| Medtronic, INC. | $26.58 | 2025 | Minimed 780g |
| Halozyme INC | $23.94 | 2023 | |
| Evoke Pharma, INC. | $23.76 | 2023 | Gimoti |
| Sequel Med Tech, LLC | $22.90 | 2025 | Twiist |
| Takeda Pharmaceuticals U.S.A., INC. | $22.24 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $21.64 | 2025 | |
| Mylan Specialty L.P. | $20.01 | 2024 | Yupelri |
| Esperion Therapeutics, INC. | $17.80 | 2023 | Nexletol |
| Astellas Pharma US INC | $17.56 | 2024 | Veozah |
| Bard Peripheral Vascular, INC. | $15.72 | 2024 | |
| Amneal Pharmaceuticals LLC | $15.60 | 2024 | Unithroid |
| Sumitomo Pharma America, INC. | $15.30 | 2024 | Gemtesa |
| Ibsa Pharma INC. | $14.91 | 2024 | Tirosint, Licart |
| Orthofix Medical, INC. | $13.94 | 2023 | Physio-Stim |
| Optos, INC. | $13.65 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Eisai INC. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.